HISOAR(SZ:002099)2022-12-19 09:30Group 1: Company Overview and Market Position - Zhejiang Haixiang Pharmaceutical Co., Ltd. is a global supplier of the full industrial chain for the Penam series, having established an independent Penam production facility in compliance with European and American drug regulations [1] - In the first three quarters of 2022, revenue from the Penam series increased by over 7% year-on-year, indicating significant growth potential as hospital admissions gradually recover [1] Group 2: Production Capacity and New Product Development - The company has completed the expansion of the entire Penam industrial chain within six months, with production capacity continuously increasing [1] - The production lines for active pharmaceutical ingredients (API) and sterile powder injections have been installed and are currently in the validation production phase [1] - The company is actively developing new products, including oral formulations and pediatric Penam, with over ten new products in the pipeline, some reaching pilot and validation production stages [2] Group 3: Research and Development Initiatives - The company is leveraging new technologies and processes to innovate existing products, reduce costs, and enhance competitiveness [2] - A new multi-functional CDMO workshop is planned to improve research and development efficiency, with the Shanghai research institute focusing on front-end process development and the Taizhou research institute on production scaling [2] Group 4: Strategic Growth and Investment - The company is committed to organic growth in the pharmaceutical sector while also considering external acquisition opportunities to strengthen its competitive advantage [2] - Suzhou Sihua, a 32.67% owned subsidiary, is performing well and represents a long-term investment for the company [2]